The first smallpox treatment, being developed for the United States government in the case of a bioterrorism attack, could be available as early as August.
The first smallpox treatment, being developed for the United States government in the case of a bioterrorism attack, could be available as early as August.
FDA granted priority review of TPOXX (SIGA Technologies), an oral antiviral treatment for smallpox, and the agency’s Antimicrobial Drugs Advisory Committee voted unanimously that the benefits of TPOXX outweigh its risks.
Related: Game-changing hep B vaccine gets FDA nod
“There are currently no approved therapies for the treatment of active smallpox disease,” Phil Gomez, PhD, CEO of SIGA Technologies, told FormularyWatch.
FDA has said it will take action on the drug by August 8, 2018.
SIGA has a $472 million procurement and development contract with the US government’s Biomedical Advanced Research and Development Authority (BARDA) for 2 million courses of oral TPOXX.
Related: Shingles vaccine wins approval
However, SIGA plans to work with FDA and determine if there is a market demand that would support TPOXX availability through typical pharmaceutical marketing channels following FDA approval, Gomez said.
“During the recent FDA Advisory Committee meetings, panel members pointed out there may be additional important indications that SIGA should explore for TPOXX after the NDA is approved. These included the use of TPOXX in outbreaks of monkeypox, which have occurred in Africa, and the use of TPOXX in post-exposure prophylaxis, essentially treating those potentially exposed to smallpox, but not yet symptomatic,” Gomez said.
SIGA also has a development contract with the US government for an intravenous formulation of TPOXX, for individuals who cannot take TPOXX capsules.
Read more: First Zika test for blood donations wins nod from FDA
FDA Approves Two More Denosumab Biosimilars, Conexxence and Bomyntra
March 27th 2025The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, as a result of a global settlement with Amgen, according to a company news release.
Read More
FDA Approves First Drug for Excess Hunger in Prader-Willi Syndrome
March 27th 2025Vykat XR will be available in April to treat the intense hunger that is a hallmark of the rare genetic disease Prader-Willi syndrome. The price is based on a patient’s weight, and the average patient in the clinical trials would have had an average annual cost of $466,200 for the first year.
Read More
FDA Approves Amvuttra for ATTR-CM in Extended Label
March 21st 2025This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
Read More